Imavita combines classical bioanalysis with near-infrared imaging to deliver organ-resolved, longitudinal PK and biodistribution data. Our end-to-end studies (sampling, in vivo/ex vivo imaging, and ELISA bridging) make PK

Chronic inflammatory skin diseases, such as atopic dermatitis, psoriasis, acne, or pemphigus vulgaris, significantly impact patients’ quality of life and overall health. To better understand these conditions and

This joint study by Imavita and the biopharmaceutical group Ipsen, published in late 2023 in Toxicon, compares the effects of a single injection of aboBoNT-A (botulinum toxin)

How IMAVITA applies the 3Rs in preclinical studies thanks to its models and the use of imaging Applying the 3Rs in preclinical studies: IMAVITA’s vision and practices Before

👩‍🔬👨‍🔬 Meet the faces behind the science! At Imavita, our greatest strength is our team. Behind every study, every image, and every result, there’s a group of passionate

Unlocking Reliable Preclinical Studies with Imavita’s Quality Management System (QMS) At Imavita, our commitment to quality is at the heart of everything we do. As a preclinical CRO,

All the team from Imavita joins me to wish you a happy and successful new year 2025!A lot of exciting news to come on 2025! Follow us on

All the team at Imavita joins me to wish you season’s greetings.We’ve had a great year at Imavita with bigger facilities, exciting developments and new collaborators.Wishing you a

We’ve Moved! We are excited to announce that Imavita has a new home!As part of our ongoing growth and commitment to serving our clients, we have relocated to